Cervical cancer screening. On organization


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Despite the available opportunities for screening for cervical cancer, this disease in Russia is diagnosed at late stages in almost a third of cases. The paper deals with the organization of cervical cancer screening as a highly effective procedure for early detection of abnormal changes. It analyzes publications from the PubMed, eLibrary, Cochrane, and CyberLeninka databases during the past 10 years. There are statistical data proving the effectiveness of cervical cancer screening in Russia. The essential components of successful cytology screening are determined. Emphasis is laid on the need for organized cervical cancer screening programs. Much attention is paid to the choice of the optimal method for diagnosing cervical pathology: the parameters and results of conventional and liquid-base cytology are compared. The lack of reliable advantages of a particular procedure is shown. There is a need for the maximum possible coverage of the female population by medical examinations as an essential component of high-quality screening, regardless of the method used. Consideration is given to the reasons for ignoring screening programs by reproductive-aged women and, as a result, the low coverage of the population by preventive medical examinations. The expediency of HPV testing at the cervical screening stage is discussed. Conclusion. The obstacles to effective cervical cancer screening, which are discussed in the article, and the indicated ways for their elimination can be used to improve the system of All-Russian screening.

Full Text

Restricted Access

About the authors

Olga V. Smetanina

Volga Research Medical University, Ministry of Health of the Russian Federation

Email: smetanina.olga3@gmail.com
a member of the scientific society of yo

Darya A. Kuzminykh

Volga Research Medical University, Ministry of Health of the Russian Federation

Email: darya.kuzminykhi@yandex.ru
a member of the scientific society of young scientists and students

Svetlana V. Smetanina

Nizhny Novgorod Regional Clinical Oncology Dispensary

Email: smetanina-svetlana@rambler.ru
Head of the Cytological Laboratory

Sergey V. Gamayunov

Nizhny Novgorod Regional Clinical Oncology Dispensary

Email: gamajnovs@mail.ru
MD, PhD, Head physician

Evgenia Yu. Uskova

Nizhny Novgorod Regional Clinical Oncology Dispensary

Email: muza-nk@mail.ru
Cytology laboratory doctor

References

  1. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 236 с. [Kaprin A.D., Starinsky V.V., Petrova G.V., ed. The state of oncological care for the population of Russia in 2018. Moscow: P.A. Herzen Moscow State Medical Research Institute - branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of Russia. 2019; 236 p. (in Russian)].
  2. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность), М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 250c. [Kaprin A.D., Starinsky V.V., Petrova G.V., ed. Malignant neoplasms in Russia in 2018 (morbidity and mortality), Moscow: P.A. Herzen Moscow State Medical Research Institute - branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of Russia. 2019; 250 p. (in Russian)].
  3. WHO. Draft: Global strategy towards the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2019. Available at: https://www.who. int/publications/m/item/draft-global-strategy-towards-eliminating-cervical-cancer-as-a-public-health-problem
  4. Australian Institute of Health and Welfare. Analysis of cervical cancer and abnormality outcomes in an era of cervical screening and HPV vaccination in Australia. Canberra: AIHW; 2019. Available at: https://www.aihw.gov. au/getmedia/479cc5bb-d698-4ff7-92fa4be451b1897b/aihw-can-129.pdf. aspx?inline=true
  5. Wild C.P, Weiderpass E., Stewart B.W. World cancer report: cancer research for cancer prevention. Lyon, France: IARS; 2020.
  6. Danckert B., Ferlay J., Engholm G., Hansen H.L., Johannesen T.B., Khan S. et al. NORDCAN: Cancer incidence, mortality, prevalence and survival in the nordic countries. Association of the Nordic Cancer Registries, Danish Cancer Society; 2019.
  7. Chan C.K., Aimagambetova G., Ukybassova T., Kongrtay K., Azizan A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination-review of current perspectives. J. Oncol. 2019; 2019: 3257939. https://dx.doi.org/10.1155/2019/3257939.
  8. Григорьева К.Н. Георгиос Николау Папаниколау (1883-1962). Акушерство, гинекология и репродукция. 2020; 14(1): 112-6. [Grigor'eva K.N. Georgios Nicolaou Papanikolaou (1883-1962). Obstetrics, Gynecology and Reproduction. 2020; 14(1): 112-6. (in Russian)]. 10.17749/2313-7347.2020.14.1.112-116.
  9. Новик В.И. Эпидемиология рака шейки матки, факторы риска, скрининг. Практическая онкология. 2002; 3(3): 156-65. [Novik V.I. Epidemiology of cervical cancer, risk factors, screening. Practical oncology. 2002; 3(3): 156-65. (in Russian)].
  10. Сагайдак B.H., Комарова Л.Е. Цитологический скрининг рака шейки матки. Вестник ОНЦ АМН России. 1992; 4: 43-8. [Sagaidak V.H., Komarova L.E. Cytological screening of cervical cancer. Bulletin of the ONC AMS of Russia. 1992; 4: 43-8. (in Russian)].
  11. Деражне А.Б., Иока Н.М., Нисенбаум Г.Э., Фридман П.Ш. Двадцатилетний опыт профилактики РШМ среди женщин, обслуживаемых лечебно-профилактическими учреждениями Октябрьской железной дороги. В кн.: Всесоюзный симпозиум «Ранняя диагностика, лечение предопухолевых и опухолевых заболеваний шейки матки и диспансеризация женского населения». Л.; 1985: 84-5. [Derazhne A.B., Ioka N.M., Nisenbaum G.E., Fridman P.SH. Twenty-year experience in preventing breast cancer among women served by medical and preventive institutions of the Oktyabrskaya Railway. L.: All-Union symposium "Early diagnosis, treatment of precancerous and tumor diseases of the cervix and medical examination of the female population". 1985; 84-5. (in Russian)].
  12. Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Pineros M. et al. Global cancer observatory: cancer today. Lyon, France: IARC; 2018.
  13. Ronco G., Rossi G.P. Role of HPV DNA testing in modern gynaecological practice. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 47: 107-18. https:// dx.doi.org/10.1016/j.bpobgyn.2017.08.002.
  14. Российское общество акушеров-гинекологов. Клинические рекомендации. Цервикальная интраэпителиальная неоплазия, эрозия и эктропион шейки матки. М.; 2020. 59c. [Russian Society of Obstetricians and Gynecologists. Clinical recommendations: Cervical intraepithelial neoplasia, erosion and ectropion of the cervix. 2020; 59 p. (in Russian)].
  15. Clarke M.A., Cheung L.C., Castle P.E., Schiffman M., Tokugawa D., Poitras N. et al. Five-year risk of cervical precancer following p16/Ki-67 dual-stain triage of HPV-positive women. JAMA Oncol. 2019; 5(2): 181-6. https://dx.doi. org/10.1001/jamaoncol.2018.4270.
  16. Li Y.C., Zhao Y.Q., Li T.Y., Chen W, Liao G.D., Wang H.R. et al. The performance of immunocytochemistry staining as triaging tests for high-risk HPV-positive women: A 24-month prospective study. J. Oncol. 2020; 2020: 6878761. https://dx.doi.org/10.1155/2020/6878761.
  17. US Preventive Services Task Force; Curry S.J., Krist A.H., Owens D.K., Barry M.J., Caughey A.B., Davidson K.W. et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018; 320(7): 674-86. https://dx.doi.org/10.1001/jama.2018.10897.
  18. Ronco G., Arbyn M., Meijer C.J.L.M., Snijders P.J.F., Cuzick J. Screening for cervical cancer with primary testing for human papillomavirus. In: Anttila A., Arbyn M., de Vuyst H., Dillner J., Dillner L., Franceschi S. et al., eds. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Suppl. 1: Office for Official Publications of the European Union. Luxembourg; 2015: 1-68.
  19. Benevolo M., Mancuso P., Allia E., Gustinucci D., Bulletti S., Cesarini E. et al.; New Technologies for Cervical Cancer 2 (NTCC2) Working Group. Determinants of p16/Ki-67 adequacy and positivity in HPV-positive women from a screening population. Cancer Cytopathol. 2020 Nov 3. https://dx.doi.org/10.1002/cncy.22385.
  20. Барчук А.А., Арсеньев А.И., Беляев А.М., Гомболевский В.А., Нефедова А.В., Канаев С.В., Барчук А.С., Щербаков А.М., Нефедов А.О., Тарков С.А., Гагуа К.Э., Костицын К.А. Эффективность скрининга онкологических заболеваний. Вопросы онкологии. 2017; 63(4): 557-67. [Barchuk A.A., Arsen'ev A.I., Belyaev A.M. et al. The effectiveness of cancer screening. Questions of oncology. 2017; 63(4): 557-67. (in Russian)].
  21. Коннон С.Р.Д., Союнов М.А. Рак шейки матки: профилактика и скрининг (новые данные). Акушерство и гинекология: новости, мнения, обучение. 2018; 6(3): 72-82. [Konnon S.R.D., Soyunov M.A Cervical cancer: prevention and screening (new data). Obstetrics and Gynecology: News, Opinions, Training. 2018; 6(3): 72-82. (in Russian)]. https://dx.doi.org/10.24411/2303-9698-2018-13008.
  22. Новик В.И., Владимирова А.В., Нефедова А.В., Красильникова Л.А. Сравнение результатов традиционной и жидкостной цитологии при проведении скрининга рака шейки матки. В кн.: Тезисы докладов IV Петербургского международного онкологического форума «Белые ночи 2018». СПб.; 2018: 58. [Novik V.I., Vladimirova A.V., Nefedova A.V., Krasilnikova L.A. Comparison of the results of traditional and liquid cytology in the screening of cervical cancer. Proceedings of the IV St. Petersburg International Cancer Forum "White Nights 2018". 2018; 58 p. (in Russian)].
  23. Елгина С.И., Золоторевская О.С., Захаров И.С., Мозес В.Г., Рудаева Е.В., Разумова В.А., Кратовский А.Ю. Цитологический скрининг в диагностике рака шейки матки. Мать и дитя в Кузбассе. 2019; 3: 37-40. [Elgina S.I., Zolotorevskaya O.S., Zakharov I.S., Mozes V.G., Rudaeva E.V., Razumova V.A., Kratovsky A.Yu. Cytological screening in the diagnosis of cervical cancer. Mother and child in Kuzbass. 2019; 3:37-40. (in Russian)].
  24. Hosono S., Terasawa T., Katayama T., Sasaki S., Hoshi K., Hamashima C. Frequency of unsatisfactory cervical cytology smears in cancer screening of Japanese women: A systematic review and meta-analysis Tokyo, Japan. Cancer Sci. 2018; 109(4): 934-43. https://dx.doi.org/10.1111/cas.13549.
  25. Kituncharoen S., Tantbirojn P., Niruthisard S. Comparison of unsatisfactory rates and detection of abnormal cervical cytology between conventional papanicolaou smear and liquid-based cytology (Sure Path®). Asian Pac. J. Cancer Prev. 2015; 6(18): 8491-4. https://dx.doi.org/10.7314/apjcp.2015.16.18.8491.
  26. Koliopoulos G., Nyaga V.N., Santesso N., Bryant A., Martin-Hirsch P.P., Mustafa R.A. et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst. Rev. 2017; (8): CD008587. https://dx.doi.org/10.1002/14651858.CD008587.pub2.
  27. Короленкова Л.И. Концептуальный подход к улучшению цервикального скрининга и ранней диагностики предрака и рака шейки матки. X съезд онкологов России. Нижний Новгород, 17-19 апреля 2019 г. М.: Медицинское Маркетинговое Агентство; 2019. [Korolenkova L.I. A conceptual approach to improving cervical screening and early diagnosis of precancerous and cervical cancer: X Congress of Oncologists of Russia, Nizhny Novgorod, April 17-19, 2019. Moscow: Medical Marketing Agency. 2019; 178 p. (in Russian)].
  28. Шабалова И.П., Ледина А.В., Созаева Л.Г., Шипулина О.Ю., Космачева Н.В., Серегина П.Е., Лешкина Г.В. Рак шейки матки в XXI веке: гинеколог, клинический цитолог, специалист по молекулярным исследованиям. Новости клинической цитологии России. 2018; 22(3-4): 31-6. [Shabalova I.P., Ledina A.V., Sozaeva L.G. et al. Cervical cancer in the XXI century: gynecologist, clinical cytologist, specialist in molecular research. News of clinical cytology in Russia. 2018; 22 (3-4). (in Russian)].
  29. Everett T., Bryant A., Griffin M.F., Martin-Hirsch P.P., Forbes C.A., Jepson R.G. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst. Rev. 2011; (5): CD002834. 10.1002/14651858. CD002834.pub2.
  30. Минкина Г.Н. Цитологический скрининг рака шейки матки: от традиционного ПАП-теста к компьютерным технологиям. Акушерство, гинекология и репродукция. 2017; 11(1): 56-63. [Minkina G.N. Cytological screening of cervical cancer: from the traditional PAP test to computer technologies. Obstetrics, gynecology, and reproduction. 2017; 11(1): 56-63. (in Russian)].
  31. Stoler M.H., Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285(11): 1500-5.
  32. Anttila A., Pokhrel A., Kotaniemi-Talonen L., Hakama M., Malila N., Nieminen P Cervical cancer patterns with automation-assisted and conventional cytological screening: a randomized study. Int. J. Cancer. 2011; 128(5): 1204-12. https:// dx.doi.org/10.1002/ijc.25677.
  33. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N. et al. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann. Oncol. 2010; 21(3): 448-58. https://dx.doi. org/10.1093/annonc/mdp471.
  34. Ronco G., Cuzick J., Pierotti P., Cariaggi M.P., Dalla Palma P., Naldoni C. et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007; 335(7609): 28. https://dx.doi.org/10.1136/bmj.39196.740995.BE.
  35. Phaliwong P., Pariyawateekul P., Khuakoonratt N., Sirichai W., Bhamarapravatana K., Suwannarurk K. Cervical cancer detection between conventional and liquid based cervical cytology: a 6-year experience in Northern Bangkok Thailand. Asian Pac. J. Cancer Prev. 2018; 19(5): 1331-6. https:// dx.doi.org/10.22034/APJCP.2018.19.5.1331.
  36. Паяниди Ю.Г., Жорданиа К.И., Савостикова М.В., Маргарян А.Г. Рак шейки матки в России. Пути профилактики. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2015; 26(1): 33-42. [Payanidi Yu.G., Zhordania K.I., Savostikova M.V., Margaryan A.G. Cervical cancer in Russia. Ways of prevention. Bulletin of the N. N. Blokhin Russian Research Center of the Russian Academy of Medical Sciences. 2015; 26 (1): 33-42. (in Russian)].
  37. Мазитова М.И., Бикинеев М.С. Этапы развития цитологического скрининга рака шейки матки. Русский медицинский журнал «Мать и дитя». 2019; 2(4): 322-6. [Mazitova M.I., Bikineev M.S. Stages of development of cytological screening of cervical cancer. Russian Medical Journal Mother and child. 2019; 2(4): 322-6. (in Russian)].
  38. Сулейманова Н.Д., Хархачаева С.М., Шахсинова Р.Н., Хархаров А.Г., Лешкина Г.В., Джаппарова К.Р. Оценка результатов внедрения жидкостной цитологии в Республике Дагестан как метода скрининга рака шейки матки. Вестник Дагестанской государственной медицинской академии. 2019; 4: 38-43. [Sulejmanova N.D., Harkhachaeva S.M., Shakhsinova R.N., Kharkharov A.G., Leshkina G.V., Dzhapparova K.R. Evaluation of the results of the introduction of liquid cytology in the Republic of Dagestan as a method of screening for cervical cancer. Bulletin of the DSMA. 2019; 4(33): 38-43. (in Russian)].
  39. Казаишвили Т.Н. Ранняя диагностика рака шейки матки методом жидкостной цитологии. Исследования и практика в медицине. 2016; Спецвыпуск (I Национальный конгресс «Онкология репродуктивных органов: от профилактики и раннего выявления к эффективному лечению» Москва, 19-21 мая 2016 г.): 80-1. [Kazaishvili T.N. Early diagnosis of cervical cancer by liquid cytology. Research'n Practical Medicine Journal. 2016; 80-1. (in Russian)].
  40. Милованов В.В. Централизация и стандартизация скрининговых исследований. Положительный опыт Тамбовской области. VI Международный Петербургский онкологический форум «Белые ночи». Санкт-Петербург, 25-28 июня 2020. СПб.: АННМО «Вопросы онкологии»; 2020. [Milovanov V.V. Centralization and standardization of screening studies. Positive experience of the Tambov region. VI International St. Petersburg Cancer Forum "White Nights", St. Petersburg, June 25-28, 2020. ANNMO "Issues of oncology". 2020; 426 p. (in Russian)].
  41. Ежова Е.Н. Менеджмент цитологической лаборатории в условиях скрининга. VI Российский конгресс лабораторной медицины, IV Форум «Клиническая цитология». Москва, 28 июля 2020. https://congress.fedlab. ru/online/july-28/?clear_cache=Y [Ezhova E.N. Management of the cytology laboratory in the screening environment. VI Russian Congress of Laboratory Medicine, IV Forum "Clinical Cytology", Moscow, July 28, 2020. https:// congress.fedlab.ru/online/july-28/?clear_cache=Y (in Russian)].
  42. Каприн А.Д., Новикова Е.Г., Трушина О.И., Грецова О.П. Скрининг рака шейки матки - нерешенные проблемы. Исследования и практика в медицине. 2015; 2(1): 36-41. [Kaprin A.D., Novikova E.G., Trushina O.I., Grecova O.P. Cervical cancer screening-unresolved issues. Research'n Practical Medicine Journal. 2015; 2(1): 36-41. (in Russian)].
  43. Волченко Н.Н., Глухова Ю.К. Проект программы национального цитологического скрининга рака шейки матки. Новости клинической цитологии России. 2018; 22(3-4): 22-30. [Volchenko N.N., Glukhova Yu.K. Project of the national cytological screening program for cervical cancer. Russian Clinical Cytology News. 2018; 22 (3-4): 22-30. (in Russian)].
  44. WHO. Comprehensive сervical сancer сontrol: A guide to essential practice. Geneva: 2014. Available at: https://apps.who.int/iris/bitstream/hand le/10665/144785/9789241548953_eng.pdf?sequence=1&isAllowed=y
  45. WHO. WHO report on cancer: setting priorities, investing wisely and providing care for all. Geneva; 2020. Available at: https://www.who.int/publications/i/ item/who-report-on-cancer-setting-priorities-investing-wisely-and-providing-care-for-all
  46. Maza M., Melendez M., Masch R., Alfaro K., Chacon A., Gonzalez E. et al. Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador. Prev. Med. 2018; 114:149-55. https://dx.doi.org/10.1016/j.ypmed.2018.06.017.
  47. Catarino R.R., Vassilakos P.P., Royannez-DrevardI.I., Guillot C.C., Alzuphar S.S., Fehlmann A.A. et al. Barriers to cervical cancer screening in Geneva (DEPIST Study). J. Low. Genit. Tract Dis. 2017; 21(2): 162. https://dx.doi.org/10.1097/ LGT.0000000000000173.
  48. VivianoM., CatarinoR., JeannotE., BoulvainM., MalinvernoM.U., Vassilakos., Petignat P. Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial. Br. J. Cancer. 2017; 116(11): 1382-8. https://dx.doi.org/10.1038/bjc.2017.111.
  49. Musa J., Achenbach C.J., O’Dwyer L.C., Evans C.T., McHugh M., Hou L. et al. Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis. PLoS One; 2017; 12(9): e0183924. https://dx.doi.org/10.1371/journal.pone.0183924.
  50. Virtanen A., Anttila A., Luostarinen T., Malila N., Nieminen P. Improving cervical cancer screening attendance in Finland. Int. J. Cancer. 2015; 136(6): E677-84. https://dx.doi.org/10.1002/ijc.29176.
  51. Saei Ghare Naz M., Kariman N., Ebadi A., Ozgoli G., Ghasemi V., Rashidi Fakari F. Educational interventions for cervical cancer screening behavior of women: A systematic review. Asian Pac. J. Cancer Prev. 2018; 19(4): 875-84. https://dx.doi.org/10.22034/APJCP.2018.19.4.875.
  52. Alfonzo E., Andersson E.A., Nemes S., Strander B. Effect of fee on cervical cancer screening attendance-Screen fee, a Swedish Population-Based Randomised Trial. PLoS One. 2016; 11(3): e0150888. https://dx.doi.org/10.1371/journal. pone.0150888.
  53. Wright T.C. Jr, Behrens C.M., Ranger-Moore J., Rehm S., Sharma A., Stoler M.H., Ridder R. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecol. Oncol. 2017; 144(1): 51-6. https://dx.doi.org/10.1016/j.ygyno.2016.10.031.
  54. Yeh P.T., Kennedy C.E., de Vuyst H., Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob. Health. 2019; 4(3): e001351. https://dx.doi.org/10.1136/bmjgh-2018-001351.
  55. Аполихина И. А., Баширова Л. К., Горбунова Е.А. Возможности приме -нения теста самозабора материала при скрининге рака шейки матки. Гинекология. 2018; 20(3): 57-60. [Apolikhina I.A., Bashirova L.K., Gorbunova E.A. The possibilities of using the self-sampling test in the screening of cervical cancer. Gynecologists. Gynecology. 2018; 3 (20): 57-60. (in Russian)].
  56. Баширова Л.К., Аполихина И.А., Павлович С.В. Скрининг рака шейки матки с использованием устройства для самозабора материала: эффективность и приемлемость. Акушерство и гинекология. 2020; 2: 50-5. [Bashirova L.K., Apolikhina I.A., Pavlovich S.V. Cervical cancer screening using a self-sampling device: effectiveness and acceptability. Obstetrics and gynecology. 2020; 2: 50-5. (in Russian)]. https://dx.doi.org/10.18565/aig.2020.2.50-61.
  57. Gizaw M., Teka B., Ruddies F., Ruddies F., Abebe T., Kaufmann A.M. et al. Uptake of cervical cancer screening in Ethiopia by self-sampling HPV DNA compared to visual inspection with acetic acid: A Cluster Randomized Trial. Cancer Prev. Res. (Philadelphia, Pa.). 2019; 12(9): 609-16. https://dx.doi.org/10.1158/1940-6207.CAPR-19-0156.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies